ASX ANNOUNCEMENT Brisbane, 4 May, 2017 ADMEDUS RELEASES RESULTS OF HSV-2 PHASE IIa STUDY Study meets primary endpoint in terms of vaccine safety Positive T-cell response in study subjects receiving vaccine Admedus Limited (ASX: AHZ) today announced the final results from its Phase IIa Herpes Simplex (HSV-2) vaccine study. The trial reached its primary endpoint of safety, with a positive immune response to the vaccine seen in most subjects. The study enrolled a total of 44 subjects, and was not designed to look at statistical significance between the vaccine and placebo for any of the endpoints. “This study is consistent with the findings from our first human study that the novel vaccine technologies that were protective in a published animal model of HSV infection appear able to induce immune responses in human subjects with HSV infection, and has provided support suggestive of a possible impact on HSV associated disease,” said Professor Ian Frazer, Chief Scientific Officer. “The research provides a foundation for Admedus Limited to consider sponsorship possibilities for a study with a large enough population to determine the efficacy of the induced immune response against HSV-2. The results warrant examination of alternative delivery approaches and dosage variations to conclude whether there is a treatment benefit in a large population,” stated CEO Wayne Paterson. An overview of results is included below. For additional data, please refer to the related webinar HSV-2 presentation slide deck. The Company is aiming to publish the complete data analysis in the future.
